APR 04, 2018 6:00 AM PDT

Proposed New Genetic-Clinical Risk Grouping Model for Prostate Cancer

WRITTEN BY: Mauri Brueggeman

Precision medicine is changing landscapes in healthcare.  One area of great interest is figuring out better ways to stratify patients into appropriate therapeutic and prognostic categories for their particular cancer.  In the March 2018 publication of the Journal of Clinical Oncology, researchers outlined the results of a new risk group classification, both developed and validated, combining clinical and genomic testing of biopsied localized prostate cancer tissue.  Prostate cancer can be aggressive or indolent; the current guides make it challenging to determine which men to monitor long term and which are at more immediate risk of death from their cancer.

The currently accepted prostate cancer treatment guidelines from the National Comprehensive Cancer Network (NCCN) include prostate-specific antigen (PSA) level, cancer grade and tumor staging as the criteria for assigning cancer patients into risk groups.  These groups have different therapeutic and prognostic implications for patients.  According to the first author of the study, Dr. Daniel Spratt included that the NCCN model is not necessarily designed to identify and predict which men will develop metastases or die of their cancer.

The researchers utilized genetic testing results evaluating the presence of 22 genes known to increase the risk of metastatic disease.  The combination of genes present provided the group an opportunity to evaluate the gene expression for nearly 7,000 men from multiple clinical sites.  Through the analysis of expression patterns, the study authors developed two new clinical-genomic system models for assigning risk to the patients.  One system had three tiers and one system had 6 tiers.  The authors evaluated the men on all three risk grouping models (NCCN, three tiered, and six-tiered) and then compared those results to patient outcomes and development of metastatic disease.  The new risk models were found, however, to be challenging to blend with the traditional NCCN guidelines so the authors have suggested combining them to create a new genomic-clinical system that standardizes the use of the biomarkers.

The results?  There were differences between the models indicating that both proposed tiered systems more accurately predicted/identified men whose disease remained slow growing and those that had more aggressive forms of prostate cancer that progressed and metastasized.  Using the six-tiered system, 67% of men would have been reclassified to the lower-risk slow-growing cancer group, meaning deferred treatment and careful monitoring of the condition.  The benefits include lowering costs, both for the patient (time, side effects, etc.) and for healthcare (fiscal, resources, etc.). 

The new model also identifies a pool of high-risk men whose disease, if only monitored, were likely to die of prostate cancer.  Providers who use these models can more accurately propose near term treatments like radiation or clinical trials and a prognosis that better match the likely progression of their disease. 

There are clear benefits to the new models including increased efficiently and precision in providing prognoses and therapy recommendations for patients; there are also increased costs up front for the healthcare system/patient for the gene expression testing for all newly diagnosed men.  There is also the challenge of creating a consensus on a new usable genetic-clinical risk system; molecular profiling is not a magic bullet and clinical evaluation must be included (PSA and Gleason score). 

Sources: Journal of Clinical Oncology, ScienceDaily, Biomedicine Hub Review,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
SEP 18, 2020
Coronavirus
How Coronavirus Spread in the US and Europe
SEP 18, 2020
How Coronavirus Spread in the US and Europe
Researchers are beginning to examine how the world's response to the pandemic virus SARS-CoV-2 went wrong, and right ...
SEP 28, 2020
Cancer
A New Transcriptomics Program in the Works Glioma Diagnosis
SEP 28, 2020
A New Transcriptomics Program in the Works Glioma Diagnosis
The future of medicine is “personalized healthcare.” However, testing remains a critical hurdle researcher&r ...
OCT 21, 2020
Cancer
Can Excess Fructose Cause Liver Cancer?
OCT 21, 2020
Can Excess Fructose Cause Liver Cancer?
Hepatocellular carcinoma, aka liver cancer, is an ever-increasing issue in the western world. While the lion’s sha ...
NOV 02, 2020
Immunology
New Cancer Drug Reboots Stalled Immunotherapies
NOV 02, 2020
New Cancer Drug Reboots Stalled Immunotherapies
In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumo ...
NOV 14, 2020
Cancer
New intravenous anti-cancer therapy crosses blood-brain barrier
NOV 14, 2020
New intravenous anti-cancer therapy crosses blood-brain barrier
New research from the University of Michigan reports for the first time a new synthetic protein nanoparticle that is abl ...
NOV 26, 2020
Immunology
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
NOV 26, 2020
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
  There’s a new weapon in the battle against lung cancer metastases: red blood cells equipped with nanopartic ...
Loading Comments...